日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Cost-effectiveness of olorofim in the treatment of invasive aspergillosis in patients with limited suitable alternative treatment options: a US payer perspective

奥洛芬治疗侵袭性曲霉病且其他治疗选择有限的患者的成本效益分析：美国支付方的视角

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.00570-25
Walsh, Thomas J; Coleman, Craig I; Blissett, Rob; Prawitz, Thibaud; Bonetti, Giuseppe; Aguiar, Magda; Bresnik, Mark; Lovelace, Belinda
发表日期：2025
文献求助 收藏

Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison

帕纳替尼与伊马替尼作为费城染色体阳性急性淋巴细胞白血病一线治疗的比较：一项匹配调整的间接比较研究

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-023-02497-y
Ribera, Josep-Maria; Prawitz, Thibaud; Freitag, Andreas; Sharma, Anuj; Dobi, Balázs; Rizzo, Federica; Sabatelli, Lorenzo; Patos, Petros
白血病
细胞生物学
发表日期：2023
文献求助 收藏

Control of COVID-19 Outbreaks under Stochastic Community Dynamics, Bimodality, or Limited Vaccination

在随机社区动力学、双峰分布或有限疫苗接种条件下控制 COVID-19 疫情

期刊:Advanced Science
影响因子:14.1
doi:10.1002/advs.202200088
Goldenbogen, Björn; Adler, Stephan O; Bodeit, Oliver; Wodke, Judith A H; Escalera-Fanjul, Ximena; Korman, Aviv; Krantz, Maria; Bonn, Lasse; Morán-Torres, Rafael; Haffner, Johanna E L; Karnetzki, Maxim; Maintz, Ivo; Mallis, Lisa; Prawitz, Hannah; Segelitz, Patrick S; Seeger, Martin; Linding, Rune; Klipp, Edda
发表日期：2022
文献求助 收藏

Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison

Tafasitab联合来那度胺与3种基于利妥昔单抗的治疗方案治疗不适合移植的复发/难治性弥漫性大B细胞淋巴瘤：一项匹配调整的间接比较研究

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-022-02094-5
Cordoba, Raul; Prawitz, Thibaud; Westley, Tracy; Sharma, Anuj; Ambarkhane, Sumeet; Kapetanakis, Venediktos; Sabatelli, Lorenzo
B细胞
细胞生物学
淋巴瘤
免疫/内分泌
发表日期：2022
文献求助 收藏

DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma

DREAMM-2：Belantamab Mafodotin 与 Selinexor + 地塞米松及标准治疗方案在复发/难治性多发性骨髓瘤中的间接比较

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-021-01884-7
Prawitz, Thibaud; Popat, Rakesh; Suvannasankha, Attaya; Sarri, Grammati; Hughes, Rachel; Wang, Feng; Hogea, Cosmina; Ferrante, Shannon Allen; Gorsh, Boris; Willson, Jenny; Kapetanakis, Venediktos
多发性骨髓瘤
骨髓瘤
发表日期：2021
文献求助 收藏